The use of beta-interferon-lb in children and adolescents with multiple sclerosis

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 106, Issue 9, 2006, Pages

  Bykova, O V ^a   Kuzenkova, L M ^a   Maslova, O I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA SERINE; INTERFERON BETA-1B;

ADOLESCENT; ARTICLE; CHILD; DEPRESSION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PSYCHOLOGICAL ASPECT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; CHILD; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS;

EID: 69149102102     PISSN: 19977298     EISSN: 19977298     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Russian source
2. Russian source
3. Russian source
4. Adams A.B., Tyor W.R., Holden K.R. Interferon bets-1b and childhood multiple sclerosis. Pedlat Neurol 1999; 21: 481-483.
5. Banwell B., Reder A.T., Krupp L. et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006; 66: 472-476.
6. Ebers G., Rice G., Wolf Ch. et al. 16-year long-term follow-up of interferon beta-1b treatment of patients with multiple sclerosis. ECTRIMS Congress, 21st. Greece (Thesaloniki) 2005.
7. Etheridge L.J., Beverley D.W., Ferrie C., McManus E. The use of interferon beta in relapsing-remitting multiple sclerosis. Arch Dis Child 2004; 89: 8: 789-791.
8. Gusev E., Boiko A., Bikova O. et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 2002; 104: 203-207.
9. Guseva M.E. Multiple sclerosis epidemiology and clinical course in children in Russia. In:. Multiple sclerosis in Europe: an epidemiological update. Eds. W. Firnhaber, K. Lauer. Leuchtturm-Verlag: LTV Press 1994; 231-235.
10. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
11. McDonald W.I., Compston A., Edan G. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel of the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
12. Mikaetoff Y., Moreau T., Debouserie M. et al. Interferon-b treatment in patients with childhood-onset multiple sclerosis. J Pediat 2001; 139: 3: 443-446.
13. Pinhas-Hamiel O., Barak Y., Sierher I., Achiron A. Juvenile multiple sclerosis: clinical features and prognostic characteristics. J Pediat 1998; 132: 735-737.
14. Pinhas-Hamiel O., Sarova-Pinhas I., Achrion A. Multiple sclerosis in childhood and adolescence: Clinical features and management. Paediat Drugs 2001; 3: 5: 329-336.
15. Rieckman P., Toyka K.V. Escalating immunothepapy of multiple sclerosis. Austrian-German-Swiss Multiple sclerosis Therapy Consensus Group (MSTCG). Eur Neurol 1999; 42: 3: 121-127.
16. Sadovnick A.D., Ebers G.C. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993; 20: 17-29.
17. Shaw C.M., Alvord E.C. Multiple sclerosis beginning in infancy. 3 Child Neurol 1987; 2: 252-256.
18. Talab R.T., Talabova M.T. Multiple sclerosis in childhood, treatment experience and side effects Serdova (Hradec Kralove, CZ). Presented at Congress, 11th ENS. France (Paris) 2001.
19. Tenenbaum S.N., Segura M.J., Fejerman N. Disease-modifying therapies in childhood and juvenile multiple sclerosis. Mult Scler 2001; 7: S7.
20. Tenenbaum S.N., Segura M.J., Fejerman N. Tolerability and efficacy of disease-modifying therapies in childhood and juvenile multiple sclerosis. Presented at Congress, 53rd AAN, USA. Philadelphia 2001. Pennsylvania. Neurology 2001; 56: Suppi 3: A361: Abstr P05.119.